| Tall Pines Medical Inc | |
|
714 Mechem Dr Ruidoso NM 88345-6905 | |
| (575) 257-4061 | |
| (575) 257-4445 |
| Full Name | Tall Pines Medical Inc |
|---|---|
| Speciality | Family Medicine |
| Location | 714 Mechem Dr, Ruidoso, New Mexico |
| Authorized Official Name and Position | Ann Spence (OFFICE MANAGER) |
| Authorized Official Contact | 5752574061 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Tall Pines Medical Inc 714 Mechem Dr Ruidoso NM 88345-6905 Ph: (575) 257-4061 | Tall Pines Medical Inc 714 Mechem Dr Ruidoso NM 88345-6905 Ph: (575) 257-4061 |
| NPI Number | 1750490017 |
|---|---|
| Provider Enumeration Date | 08/30/2006 |
| Last Update Date | 02/16/2012 |
| Medicare PECOS PAC ID | 5890743504 |
|---|---|
| Medicare Enrollment ID | O20050110000769 |
News Archive
HemaCare Corporation today announced an agreement with Dendreon Corporation to provide cellular collection services in Los Angeles and Maine for their new autologous cellular immunotherapy, PROVENGE® (sipuleucel-T). This personalized medicine is Dendreon's lead product and is the first autologous cellular immunotherapy specifically designed to engage patients' own immune systems to treat cancer.
The risk of death following bone marrow transplantation can be reduced about 60 percent using a new technique to identify bone marrow donors who make the most potent cancer-fighting immune cells, according to research from St. Jude Children's Research Hospital. The findings appear in the September 16 online issue of the Journal of Clinical Oncology.
James A. Wells, professor and chairman of the department pharmaceutical chemistry at the University of California, San Francisco, and director of UCSF's small molecule discovery center, has been named the winner of the 2010 American Society for Biochemistry and Molecular Biology-Merck Award for his pioneering studies in the field of protein engineering.
An analysis of Medicare data from 1993 through 2006 for older patients hospitalized for heart failure indicates that along with a decrease in hospital length of stay, the rate of in-hospital and 30-day mortality has decreased, while the rate of hospital readmission and discharge to skilled nursing facilities has increased, according to a study in the June 2 issue of JAMA.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750490017 | NPI | - | NPPES |
| 03020 | Medicaid | NM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 88-74 (New Mexico) | Primary |
| Provider Name | Michael D Spence |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1992706352 PECOS PAC ID: 0345298063 Enrollment ID: I20050110000910 |
News Archive
HemaCare Corporation today announced an agreement with Dendreon Corporation to provide cellular collection services in Los Angeles and Maine for their new autologous cellular immunotherapy, PROVENGE® (sipuleucel-T). This personalized medicine is Dendreon's lead product and is the first autologous cellular immunotherapy specifically designed to engage patients' own immune systems to treat cancer.
The risk of death following bone marrow transplantation can be reduced about 60 percent using a new technique to identify bone marrow donors who make the most potent cancer-fighting immune cells, according to research from St. Jude Children's Research Hospital. The findings appear in the September 16 online issue of the Journal of Clinical Oncology.
James A. Wells, professor and chairman of the department pharmaceutical chemistry at the University of California, San Francisco, and director of UCSF's small molecule discovery center, has been named the winner of the 2010 American Society for Biochemistry and Molecular Biology-Merck Award for his pioneering studies in the field of protein engineering.
An analysis of Medicare data from 1993 through 2006 for older patients hospitalized for heart failure indicates that along with a decrease in hospital length of stay, the rate of in-hospital and 30-day mortality has decreased, while the rate of hospital readmission and discharge to skilled nursing facilities has increased, according to a study in the June 2 issue of JAMA.
› Verified 6 days ago
| Provider Name | Ann Renee Taylor |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1467430454 PECOS PAC ID: 3375452402 Enrollment ID: I20150115001731 |
News Archive
HemaCare Corporation today announced an agreement with Dendreon Corporation to provide cellular collection services in Los Angeles and Maine for their new autologous cellular immunotherapy, PROVENGE® (sipuleucel-T). This personalized medicine is Dendreon's lead product and is the first autologous cellular immunotherapy specifically designed to engage patients' own immune systems to treat cancer.
The risk of death following bone marrow transplantation can be reduced about 60 percent using a new technique to identify bone marrow donors who make the most potent cancer-fighting immune cells, according to research from St. Jude Children's Research Hospital. The findings appear in the September 16 online issue of the Journal of Clinical Oncology.
James A. Wells, professor and chairman of the department pharmaceutical chemistry at the University of California, San Francisco, and director of UCSF's small molecule discovery center, has been named the winner of the 2010 American Society for Biochemistry and Molecular Biology-Merck Award for his pioneering studies in the field of protein engineering.
An analysis of Medicare data from 1993 through 2006 for older patients hospitalized for heart failure indicates that along with a decrease in hospital length of stay, the rate of in-hospital and 30-day mortality has decreased, while the rate of hospital readmission and discharge to skilled nursing facilities has increased, according to a study in the June 2 issue of JAMA.
› Verified 6 days ago
News Archive
HemaCare Corporation today announced an agreement with Dendreon Corporation to provide cellular collection services in Los Angeles and Maine for their new autologous cellular immunotherapy, PROVENGE® (sipuleucel-T). This personalized medicine is Dendreon's lead product and is the first autologous cellular immunotherapy specifically designed to engage patients' own immune systems to treat cancer.
The risk of death following bone marrow transplantation can be reduced about 60 percent using a new technique to identify bone marrow donors who make the most potent cancer-fighting immune cells, according to research from St. Jude Children's Research Hospital. The findings appear in the September 16 online issue of the Journal of Clinical Oncology.
James A. Wells, professor and chairman of the department pharmaceutical chemistry at the University of California, San Francisco, and director of UCSF's small molecule discovery center, has been named the winner of the 2010 American Society for Biochemistry and Molecular Biology-Merck Award for his pioneering studies in the field of protein engineering.
An analysis of Medicare data from 1993 through 2006 for older patients hospitalized for heart failure indicates that along with a decrease in hospital length of stay, the rate of in-hospital and 30-day mortality has decreased, while the rate of hospital readmission and discharge to skilled nursing facilities has increased, according to a study in the June 2 issue of JAMA.
› Verified 6 days ago
Rio Pecos Family Practice Of Lincoln County Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 159 Mescalero Trl, Ruidoso, NM 88345 Phone: 505-257-3681 Fax: 505-257-4036 | |
Lincoln County Family Medical Group Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1401 Sudderth Dr, Ruidoso, NM 88345 Phone: 575-257-7712 Fax: 575-257-4513 | |
Atrinea Ruidoso Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1401 Sudderth Dr, Ruidoso, NM 88345 Phone: 505-338-3851 Fax: 505-338-3859 | |
Health Care Solutions Pa Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 208 Porr Dr, Ruidoso, NM 88345 Phone: 575-630-1214 Fax: 575-630-2083 | |
Michael P. Clements Md Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1096 Mechem Dr Ste G05, Ruidoso, NM 88345 Phone: 575-973-5864 Fax: 575-258-2648 | |
Rejuvenation Etc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 101 Reese Dr, Ruidoso, NM 88345 Phone: 575-630-3739 Fax: 575-630-3739 |